Clinical experience with pentoxifylline

Atherosclerosis

Volumn 131, Issue SUPPL., 1997, Pages

  Labs, Karl Heinz ^a   Labs, R ^a   Roßner M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE;

BLOOD FLOW VELOCITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; INTERMITTENT CLAUDICATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; TREADMILL ERGOMETRY; TREATMENT OUTCOME;

EID: 0030751102     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)06125-X     Document Type: Conference Paper

References (15)

1. Jäger KA, Labs KH, FitzGerald DE, Labs R. Peripheral arterial occlusive disease: epidemiology, risk and hemodynamics. In: Labs KH, Schmid-Schönbein GW, Schönharting MM (Eds). Leukocytes and Endothelial Interactions. Barcelona: Prous Scientific, 1995;103.
2. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt III WF, Graor RA, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984;4:223.
3. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381.
4. O'Riordan DS, O'Donnell JA. Realistic expectations for the patient with intermittent claudication. Br J Surg 1991;78:861.
5. Bollinger A. Funktionelle Angiologie, Lehrbuch und Atlas. Stuttgart: Georg Thieme Verlag, 1979;70.
6. Heidrich H. Vasoaktive Pharmaka bei peripheren arteriellen Durchbluutungsstörungen. Probleme, Prinzipien und Ergebnisse des therapeutischen Wirksamkeitsnachweises. Dtsch Med Wschr 1985;110:1219.
7. Weidinger P, Bachl N. 5 Jahre Wiener Erfahrungen mit ambulanten Claudicatiogruppen. In: Diehm C, Gerlach HE (Eds). Bewegungstherapie bei Peripheren Arteriellen Durchblutungsstörungen. München: Zuckschwerdt Verlag, 1987;16.
8. Blair SN, Gibbons LW, Painter P, Pate RR, Barr Raylor C, Will J. Guidelines for exercise testing and prescription. Philadelphia: Lea&Febiger, 1986;157.
9. FitzGerald DE, Jäger KA, Labs KH. Peripheral arterial occlusive disease: clinical trial methodology. In: Labs KH, Schmid-Schönbein GW, Schönharting MM (Eds). Leukocytes and Endothelial Interactions. Bercelona: Prous Science, 1995;123.
10. Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, et al. Pentoxifylline efficacy in the treatment of intermittent claudication. Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982;104:66.
11. Gillings D, Koch G, Reich T, Stager WJ. Another look at the pentoxifylline efficacy data for intermittent claudication. J Clin Pharmacol 1987;27:601.
12. Lindgärde F, Jellnes R, Björkman H, Adielsson G, Kjellström T, Palmquist I, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 1989;80:1459.
13. European Agency for the Evaluation of Medicinal Products. CPMP Efficacy Working Party on the Clinical Investigation of Medicinal Products in the Treatment of Chronic Peripheral Arterial Occlusive Disease. European Agency for the Evaluation of Medicinal Products. Document CPMP/EWP/233/95.
14. Rössner M, Müller R. On the assessment of the efficacy of pentoxifylline (Trental). J Med 1987;18:1.
15. Labs KH, FitzGerald DE, Jäger KA. Therapeutic options for peripheral occlusive arterial disease. In: Labs KH, Schmid-Schönbein GW, Schönharting MM (Eds). and Endothelial Interactions. Barcelona: Prous Science, 1995;129.